Allitia Dibernardo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Janssen Receives Positive CHMP Opinion for SPRAVATO? (Esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder
vs 20.4%), respectively.
6
There is a pressing need to provide individuals with Major Depressive Disorder who are experiencing a psychiatric emergency with treatments that can rapidly reduce their depressive symptoms, said Bill Martin, Ph.D., Global Therapeutic Area Head, Neuroscience, Janssen Research Development, LLC. If approved by the European Commission, esketamine nasal spray has the potential to offer individuals relief from debilitating depressive symptoms and address a key unmet need within this population.
With this positive CHMP opinion, esketamine nasal spray will now be considered by the European Commission for adults with a moderate to severe episode of MDD, as acute, short term treatment, for the rapid reduction of depressive symptoms, which according t ....

United States , Allitia Dibernardo , Christopher Delorefice , Clin Psychopharmacol , Cristiana Maria , Clin Neurosci , Jennifer Mcintyre , Kostenloser Wertpapierhandel , Bill Martin , Janssen Cilag International , International Classification Of Diseases , Johnson Ltd , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Committee For Medicinal Products Human Use , Committee Of Medicinal Products For Human Use , Other Common Mental Health Disorders , None Of The Janssen Pharmaceutical Companies , Drug Administration , World Health Organization , European Commission , American Psychological Association , Exchange Commission , Global Health , Companies Of Johnson ,